MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

Search

Incyte Corp

Slēgts

SektorsVeselības aprūpe

86.08 1.47

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

83.31

Max

86.11

Galvenie mērījumi

By Trading Economics

Ienākumi

247M

405M

Pārdošana

163M

1.2B

P/E

Sektora vidējais

20.031

37.257

Peļņas marža

33.319

Darbinieki

2,617

EBITDA

324M

582M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+2.82% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 28. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

3B

17B

Iepriekšējā atvēršanas cena

84.61

Iepriekšējā slēgšanas cena

86.08

Ziņu noskaņojums

By Acuity

56%

44%

321 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 14. okt. 22:33 UTC

Peļņas

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

2025. g. 14. okt. 22:21 UTC

Galvenie tirgus virzītāji

Dentsply Sirona Shares Rise After SEC Probe Ends

2025. g. 14. okt. 19:27 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

2025. g. 14. okt. 17:56 UTC

Galvenie tirgus virzītāji

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

2025. g. 14. okt. 23:38 UTC

Tirgus saruna

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

2025. g. 14. okt. 22:12 UTC

Tirgus saruna
Peļņas

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

2025. g. 14. okt. 21:40 UTC

Peļņas

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

2025. g. 14. okt. 21:39 UTC

Peļņas

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

2025. g. 14. okt. 21:38 UTC

Peļņas

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

2025. g. 14. okt. 21:06 UTC

Peļņas

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

2025. g. 14. okt. 20:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 14. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 14. okt. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 14. okt. 20:50 UTC

Tirgus saruna
Peļņas

Health Care Roundup: Market Talk

2025. g. 14. okt. 20:13 UTC

Peļņas

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

2025. g. 14. okt. 20:01 UTC

Peļņas

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

2025. g. 14. okt. 19:21 UTC

Tirgus saruna
Peļņas

Citigroup's Higher Outlook Leaves Questions -- Market Talk

2025. g. 14. okt. 19:12 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

2025. g. 14. okt. 19:08 UTC

Tirgus saruna

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

2025. g. 14. okt. 19:02 UTC

Tirgus saruna

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

2025. g. 14. okt. 18:59 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

2025. g. 14. okt. 18:58 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

2025. g. 14. okt. 18:58 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

2025. g. 14. okt. 18:56 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

2025. g. 14. okt. 18:46 UTC

Peļņas

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

2025. g. 14. okt. 18:04 UTC

Peļņas

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

2025. g. 14. okt. 18:01 UTC

Tirgus saruna

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

2025. g. 14. okt. 17:54 UTC

Peļņas

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

2025. g. 14. okt. 17:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 14. okt. 17:50 UTC

Tirgus saruna

Lower Dollar Provides Some Strength in Grains -- Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

2.82% augšup

Prognoze 12 mēnešiem

Vidējais 87.12 USD  2.82%

Augstākais 115 USD

Zemākais 60 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

8

Pirkt

10

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

321 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat